Opinion

Video

Patient-Reported Outcomes and Quality of Life Data With T-DXd in HER2-(Ultra) Low mBC

Author(s):

Neil M. Iyengar, MD,Sara A. Hurvitz, MD, FACP

Panelists discuss how trastuzumab deruxtecan (T-DXd) demonstrated favorable patient-reported outcomes and quality of life measures in HER2-low hormone receptor-positive metastatic breast cancer patients in DESTINY-Breast06, suggesting it could be a well-tolerated therapeutic option that maintains patients' daily functioning while providing clinical benefit.

Video content above is prompted by the following:

What insights do the patient-reported outcomes and quality of life data from the DESTINY-Breast06 trial show, and how might these findings inform patient care?

Related Videos
5 experts are featured in this series
5 experts are featured in this series
Julie Lang, MD, discusses real-world outcomes of the neoadjuvant KEYNOTE-522 regimen in patients with early-stage triple-negative breast cancer.
Related Content
2024 FDA Approvals in Breast, Gynecologic, and Other Solid Tumors Represent Key Steps Forward
February 13th 2025

2024 FDA Approvals in Breast, Gynecologic, and Other Solid Tumors Represent Key Steps Forward

MedNews Week
January 1st 2025

DESTINY-Breast06 Data Demonstrate the Role of T-DXd in HER2-Low and -Ultralow Breast Cancer: With Chandler Park, MD; and Guiseppe Curigliano, MD, PhD

Encorafenib combination boosts survival in BRAF V600E+ mCRC, pertuzumab biosimilar BLA is under review for HER2+ breast cancer, and more from OncLive.
February 8th 2025

The OncFive: Top Oncology Articles for the Week of 2/2

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Targeted Therapies in HR+/HER2– Breast Cancer: Evidence-Based Strategies and Emerging Frontiers
February 7th 2025

Targeted Therapies in HR+/HER2– Breast Cancer

Manish R. Patel, MD, of Florida Cancer Specialists
February 5th 2025

CLDN6-Directed Agents Generate Encouraging Early Activity in Solid Tumors